Ivax Failure To Investigate Perphenazine Complaints Cited In Warning Letter
Executive Summary
Ivax' quality unit failed to investigate eight complaints of discoloration for perphenazine tablets, FDA said in a warning letter.
You may also be interested in...
Ivax Product Failure Tracking System Inadequate - FDA Warning Letter
Ivax' product failure tracking system is inadequate, an FDA warning letter to the company states.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials